Danaher (NYSE:DHR – Get Free Report) released its quarterly earnings results on Tuesday. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14, Briefing.com reports. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s revenue was up 3.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.02 earnings per share.
Danaher Stock Performance
NYSE DHR traded down $3.57 during trading hours on Wednesday, hitting $257.71. 312,830 shares of the stock were exchanged, compared to its average volume of 2,713,142. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The company has a market cap of $190.88 billion, a price-to-earnings ratio of 43.99, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. Danaher has a 12-month low of $182.09 and a 12-month high of $281.70. The stock has a 50-day moving average of $270.67 and a 200 day moving average of $260.46.
Danaher Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.42%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s payout ratio is 18.31%.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on Danaher
Insider Buying and Selling at Danaher
In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is owned by corporate insiders.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How to Use the MarketBeat Dividend Calculator
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Stock Sentiment Analysis: How it Works
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.